140 related articles for article (PubMed ID: 29100304)
1. Germline variations at
Chiang YH; Chang YC; Lin HC; Huang L; Cheng CC; Wang WT; Cheng HI; Su NW; Chen CG; Lin J; Chang YF; Chang MC; Hsieh RK; Chou WC; Lim KH; Kuo YY
Oncotarget; 2017 Sep; 8(44):76204-76213. PubMed ID: 29100304
[TBL] [Abstract][Full Text] [Related]
2. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients.
Trifa AP; Bănescu C; Bojan AS; Voina CM; Popa Ș; Vișan S; Ciubean AD; Tripon F; Dima D; Popov VM; Vesa ȘC; Andreescu M; Török-Vistai T; Mihăilă RG; Berbec N; Macarie I; Coliţă A; Iordache M; Cătană AC; Farcaș MF; Tomuleasa C; Vasile K; Truică C; Todincă A; Pop-Muntean L; Manolache R; Bumbea H; Vlădăreanu AM; Gaman M; Ciufu CM; Popp RA
Am J Hematol; 2018 Jan; 93(1):100-106. PubMed ID: 29047144
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
Tapper W; Jones AV; Kralovics R; Harutyunyan AS; Zoi K; Leung W; Godfrey AL; Guglielmelli P; Callaway A; Ward D; Aranaz P; White HE; Waghorn K; Lin F; Chase A; Baxter EJ; Maclean C; Nangalia J; Chen E; Evans P; Short M; Jack A; Wallis L; Oscier D; Duncombe AS; Schuh A; Mead AJ; Griffiths M; Ewing J; Gale RE; Schnittger S; Haferlach T; Stegelmann F; Döhner K; Grallert H; Strauch K; Tanaka T; Bandinelli S; Giannopoulos A; Pieri L; Mannarelli C; Gisslinger H; Barosi G; Cazzola M; Reiter A; Harrison C; Campbell P; Green AR; Vannucchi A; Cross NC
Nat Commun; 2015 Apr; 6():6691. PubMed ID: 25849990
[TBL] [Abstract][Full Text] [Related]
4. TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.
Matsuguma M; Yujiri T; Yamamoto K; Kajimura Y; Tokunaga Y; Tanaka M; Tanaka Y; Nakamura Y; Tanizawa Y
Int J Hematol; 2019 Dec; 110(6):690-698. PubMed ID: 31571131
[TBL] [Abstract][Full Text] [Related]
5. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
6. Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.
Koh SP; Yip SP; Lee KK; Chan CC; Lau SM; Kho CS; Lau CK; Lin SY; Lau YM; Wong LG; Au KL; Wong KF; Chu RW; Yu PH; Chow EY; Leung KF; Tsoi WC; Yung BY
BMC Genet; 2014 Dec; 15():147. PubMed ID: 25526816
[TBL] [Abstract][Full Text] [Related]
7. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
[TBL] [Abstract][Full Text] [Related]
8. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
[TBL] [Abstract][Full Text] [Related]
9. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST; Gotlib J
Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
[TBL] [Abstract][Full Text] [Related]
10. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
[TBL] [Abstract][Full Text] [Related]
11. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
[TBL] [Abstract][Full Text] [Related]
12. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
13. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
14. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
15. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
16. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
[TBL] [Abstract][Full Text] [Related]
17. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
18. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
20. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
